Expanding use of GLP-1 and insulin therapies among people who self-inject at home is the leading force behind growth in the global pen needles market. As more patients manage diabetes and other chronic conditions with self-administered injectable pens instead of in-clinic administration, the pool of buyers purchasing disposable needle attachments keeps widening. Contrive Datum Insights rates this shift as the single largest contributor to the market's expansion over the forecast period.
The global pen needles market was valued at USD 4.4 billion in 2025. It is projected to grow to USD 4.88 billion in 2026 and reach USD 10.02 billion by 2034, a compound annual growth rate of 9.41%, according to Contrive Datum Insights' report, "Pen Needles Market Size, Share & Industry Analysis, By Product type (Standard pen needles, Safety pen needles), Length (4mm, 5mm, 6mm, 8mm, 10mm, 12mm), Therapy (Insulin therapy, Glucagon-like Peptide-1 (GLP-1) therapy, Growth hormone therapy, Other therapies), Mode of purchase (Retail, Non-Retail), End user (Homecare Settings, Hospitals & Clinics, Other End Users), and Regional Forecast, 2026-2034".
Safety pen needles capture most of that growth. The line expands at 12.68% a year, well above the market average, lifting its share of revenue from 32.05% in 2025 to 42.02% by 2034 and its value from USD 1.41 billion to USD 4.21 billion. Standard pen needles still account for the bigger dollar figure today: USD 2.99 billion of the 2025 total (67.95% of revenue), and they hold onto 57.98% of the market by 2034, even though their own growth settles at 7.49%.
North America accounts for the largest regional share, 37.95% of 2025 revenue at USD 1.67 billion, climbing to USD 3.61 billion by 2034. Asia Pacific's share rises over the same period, from 24.09% to 27.05%, as its revenue more than doubles, from USD 1.06 billion to USD 2.71 billion. Middle East and Africa remains the smallest region throughout, moving only from 5% to 5.49% of global revenue.
The study also models a bear case for the market. Slower growth in GLP-1 prescribing, tighter pricing pressure from payers, and delayed regulatory adoption of safety-engineered needles would together hold 2034 revenue to USD 8.62 billion, well below the USD 10.02 billion base forecast. A faster version of the same trends, captured in the study's bull scenario, would instead lift 2034 revenue to USD 11.42 billion. How quickly GLP-1 and insulin therapy adoption continues to spread will determine which of those outcomes the market lands closer to.